XNCR Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

11.750

Open

11.750

VWAP

11.57

Vol

746.63K

Mkt Cap

849.99M

Low

11.370

Amount

8.64M

EV/EBITDA(TTM)

--

Total Shares

73.34M

EV

433.01M

EV/OCF(TTM)

--

P/S(TTM)

6.94

Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.

Show More

Events Timeline

(ET)

2026-03-09

16:10:00

Xencor Terminates Collaboration Agreement with Genentech

2026-03-08 (ET)

2026-03-08

22:30:00

KKR Plans to Sell CoolIT Systems for Over $3B

2026-03-08

17:00:00

Dr. Vinay Prasad to Leave Agency at End of April

2026-03-04 (ET)

2026-03-04

16:10:00

Xencor Expects Cash to Reach $380M to $400M by 2026

2026-02-25 (ET)

2026-02-25

16:10:00

Xencor Q4 Revenue at $28.2M, Below Consensus

2025-12-09 (ET)

2025-12-09

07:30:00

Xencor Secures U.S. Patent 12,492,253 Extending Antibody Half-Life to 2028

News

seekingalpha

03-05seekingalpha

Xencor Lowers Outlook After Royalty Dispute

Benzinga

Xencor Lowers Revenue Outlook for Ultomiris Royalties

seekingalpha

02-25seekingalpha

Xencor Q4 Earnings Beat Expectations Despite Revenue Decline

SeekingAlpha

2025-12-17SeekingAlpha

Incyte reveals EU authorization for lymphoma treatment developed in partnership with Xencor

Newsfilter

2025-12-09Newsfilter

Xencor Extends Ultomiris Patent to 2028, Anticipates $100M to $120M in Additional Revenue

Benzinga

2025-11-06Benzinga

JP Morgan Keeps Overweight Rating on Xencor, Reduces Price Target to $18

5 Analyst Rating

Wall Street analysts forecast XNCR stock price to rise

4 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

20.00

Averages

26.25

High

30.00

Current: 0.000

Low

20.00

Averages

26.25

High

30.00

Barclays

NULL -> Overweight

maintain

$26 -> $27

AI Analysis

2026-02-26

Reason

Barclays

Price Target

$26 -> $27

AI Analysis

2026-02-26

maintain

NULL -> Overweight

Reason

Barclays raised the firm's price target on Xencor to $27 from $26 and keeps an Overweight rating on the shares. The firm updated the company's model post the Q4 report.

BofA

Neutral

maintain

$17 -> $20

2026-01-06

Reason

BofA

Price Target

$17 -> $20

2026-01-06

maintain

Neutral

Reason

BofA raised the firm's price target on Xencor to $20 from $17 and keeps a Neutral rating on the shares. The firm is updating its price targets for U.S Biopharmaceuticals under its coverage, the analyst tells investors. Over the past few months, several key items "have fallen into place," including positive data catalysts being rewarded; large-cap biopharma spending cash on M&A and in-licensing; growing backlog of companies on the private side; improving access to capital; and limited impact from drug price regulation, BofA says. The firm believes biotech is back, but the biggest concern is whether this will last.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for XNCR

Unlock Now

Valuation Metrics

The current forward P/E ratio for Xencor Inc (XNCR.O) is -5.77, compared to its 5-year average forward P/E of -8.74. For a more detailed relative valuation and DCF analysis to assess Xencor Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-8.74

Current PE

-5.77

Overvalued PE

4.17

Undervalued PE

-21.65

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-1.62

Current EV/EBITDA

-3.53

Overvalued EV/EBITDA

26.36

Undervalued EV/EBITDA

-29.59

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

14.35

Current PS

9.68

Overvalued PS

20.38

Undervalued PS

8.32

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

of all the listed stocks pick one please

Intellectia · 111 candidates

Price: $5.00 - $75.00Relative Vol: >= 1.50List Exchange: XNYS, XNAS, XASEWeek Price Change Pct: >= $5.00One Day Rise Prob: >= 65Monthly Average Dollar Volume: >= 1,500,000

Ticker

Name

Market Cap$

Rayonier Advanced Materials Inc

685.47M

Adeia Inc

2.26B

Imax Corp

1.96B

Disc Medicine Inc

2.53B

Farmland Partners Inc

564.25M

Tanger Inc

4.31B

stock of the day for swing trade

Intellectia · 517 candidates

Price: $10.00 - $150.00Rsi Category: moderateRelative Vol: >= 1.50Moving Average Relationship: PriceAboveMA20One Week Predict Return: >= 0.0%Monthly Average Dollar Volume: >= 1,500,000

Ticker

Name

Market Cap$

Celldex Therapeutics Inc

2.05B

Xencor Inc

855.50M

Montrose Environmental Group Inc

826.19M

Thomson Reuters Corp

44.22B

Phathom Pharmaceuticals Inc

961.13M

CAVA Group Inc

9.94B

Whales Holding XNCR

TCG Crossover Management, LLC

BVF Partners L.P.

EcoR1 Capital, LLC

RTW Investments, LP

Trading Trends

People Also Watch

Frequently Asked Questions

What is Xencor Inc (XNCR) stock price today?

The current price of XNCR is 11.59 USD — it has decreased -1.28

What is Xencor Inc (XNCR)'s business?

Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.

What is the price predicton of XNCR Stock?

Wall Street analysts forecast XNCR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XNCR is26.25 USD with a low forecast of 20.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Xencor Inc (XNCR)'s revenue for the last quarter?

Xencor Inc revenue for the last quarter amounts to 28.24M USD, decreased -59.67

What is Xencor Inc (XNCR)'s earnings per share (EPS) for the last quarter?

Xencor Inc. EPS for the last quarter amounts to -0.09 USD, decreased -87.67

How many employees does Xencor Inc (XNCR). have?

Xencor Inc (XNCR) has 260 emplpoyees as of March 19 2026.

What is Xencor Inc (XNCR) market cap?

Today XNCR has the market capitalization of 849.99M USD.